REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
9.63
+0.07 (0.73%)
At close: Nov 20, 2024, 4:00 PM
9.35
-0.28 (-2.91%)
Pre-market: Nov 21, 2024, 7:39 AM EST
REGENXBIO Employees
REGENXBIO had 344 employees as of December 31, 2023. The number of employees decreased by 57 or -14.21% compared to the previous year.
Employees
344
Change (1Y)
-57
Growth (1Y)
-14.21%
Revenue / Employee
$245,137
Profits / Employee
-$694,201
Market Cap
477.12M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Community Health Systems | 61,000 |
Fulgent Genetics | 1,184 |
Talkspace | 472 |
Pharming Group | 382 |
PureTech Health | 90 |
Olema Pharmaceuticals | 74 |
Altimmune | 59 |
Mind Medicine (MindMed) | 57 |
RGNX News
- 3 days ago - REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA - PRNewsWire
- 7 days ago - REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202 - PRNewsWire
- 14 days ago - REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 14 days ago - REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates - PRNewsWire
- 17 days ago - REGENXBIO to Participate in Upcoming Investor Conferences - PRNewsWire
- 20 days ago - REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track - Seeking Alpha
- 22 days ago - REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights - PRNewsWire
- 4 weeks ago - REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024 - PRNewsWire